Ameretat - AI That Sees the Unseen!

Problem

Colorectal cancer is the second leading cause of cancer related death. Up to 28% of polyps are missed during colonoscopy procedures due to human factors, allowing polyps to develop into life-threatening late-stage cancers.

Solution

Ameretat is developing a real-time artificial intelligence, AI, system that analyzes colonoscopy video streams to highlight and characterize potential polyps. Our key differentiators:

High sensitivity, including flat lesions.
Real-time performance with minimal disruption.
Seamless integration into existing hospital infrastructure via cloud-based software, requiring minimal workflow changes.

Impact

Clinical Impact: Reduces polyp miss rate during colonoscopy, enabling earlier, more effective treatment.

Societal Relevance: A potential 10% improvement in polyp detection could save over 55,000 lives per year and reduce healthcare costs by more than $2.5 billion annually.

Market Access

Payers: By forming strategic partnerships with health tech providers, hospitals and screening centers will pay them directly, while we earn based on licensing agreements with partners.

Users: Gastroenterologists in hospitals and screening centers.

Differentiation: Unlike hardware solutions, our software-driven model avoids high upfront costs and enables a pay-per-procedure approach, making adoption easier and more scalable.

Traction

AI model: Developed over four years during a PhD to handle all image types and any device resolutions, performing exceptionally well even on very small datasets.

Clinical Data: Built on 14,000+ annotated polyp images from UMCG, in close collaboration with top clinicians.

Business Foundation: Over 1 year of entrepreneurial training via VentureLab, Life Cooperative, and continuing with NOM program, with multiple startup pitch competition wins.